10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics

TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.

Zacks Investment Research • Jun 19, 2026

Torex Gold Announces Results of Its 2026 Meeting of Shareholders

Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company.

Newsfile Corp • Jun 17, 2026

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

PRNewsWire • Jun 17, 2026

TXG Gains From Proteintech Deal, Expands Multiomics Capabilities

10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.

Zacks Investment Research • Jun 10, 2026

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.

PRNewsWire • Jun 9, 2026

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • Jun 4, 2026

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026

10x Genomics Q1 Earnings Call Highlights

10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.

MarketBeat • May 9, 2026

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up

TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.

Zacks Investment Research • May 8, 2026